Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for
May 10, 2017, 4:30 p.m. ET
CORALVILLE, Iowa, May 01, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quarter 2017.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 15162616
An audio webcast with slide presentation will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast and presentation will remain available for 90 days beginning at approximately 5:30 p.m. ET, on May 10, 2017.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
